Vantictumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Vantictumab Usage And Synthesis

Uses

Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2][3].

References

[1] Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830. DOI:10.1007/s10637-019-00824-1
[2] Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62. DOI:10.1007/s10549-020-05817-w
[3] Smith D C, et al. Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors[J]. Molecular Cancer Therapeutics, 2013, 12(11_Supplement): B24-B24.

Vantictumab(1345009-45-1)Related Product Information

• Tecaginlimab
• Bectumomab
• Loncastuximab
• Lirentelimab
• Demcizumab
• Bermekimab
• Pidilizumab
• Nerelimomab [usan:inn]
• Rocatinlimab
• Astegolimab